Precision immunology company Scipher Medicine has introduced the ClinicalTrialRank.com AI platform to the public.

A501, which was placed on hold due to a patient death, will now resume with a reduced dose and altered regimen.

The long-term data supports the drug’s progression into the HEALEY ALS Platform trial, with NUZ-001 dosing set to commence in Q4 2025. This will only begin, however, if the US Food and Drug ...

Celldex will stop development of barzolvolimab in eosinophilic esophagitis, but it will continue progressing the drug in ...

The FDA has announced it will no longer accept clinical trials that involve sending US patients cells from US to China for ...

MTPA's oral therapy Radicava (edaravone) has shown decreased functional decline and improved survival in long-term ALS trials ...

Degrees Pharmaceuticals has entered into a clinical study agreement with the Icahn School of Medicine at Mount Sinai in the ...

A recently published study provides an incentive to explore what specific aspects of vegetarianism are protective.

Biodexa has enrolled the initial two subjects in the Phase III Serenta study of eRapa, involving individuals with FAP.

BioAge Labs has dosed the first subject in the Phase I study of BGE-102, under development initially for treating obesity.

Anocca has secured approximately Skr440m (around $46m) to primarily support the early-stage clinical trials of VIDAR-1.

This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.